SAN DIEGO, Aug. 27 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Theodore Schroeder will present the company's corporate overview on Thursday, September 4 at 4:00pm Eastern Time (1:00pm Pacific Time) during the 2008 NewsMakers In the Biotech Industry Conference at the Millennium Broadway Hotel in New York City.
The presentation will be simultaneously webcast and can be accessed on Cadence Pharmaceuticals' website at http://www.cadencepharm.com in the Investor Relations section. A replay of the webcast will be available approximately three hours following the live webcast and will be archived for 90 days.
About Cadence Pharmaceuticals, Inc.
Cadence Pharmaceuticals is a biopharmaceutical company focused on
in-licensing, developing and commercializing proprietary product candidates
principally for use in the hospital setting. The company currently has two
Phase III product candidates in development, Acetavance(TM) (intravenous
acetaminophen) for the treatment of acute pain and fever, and Omigard(TM)
(omiganan pentahydrochloride 1% topical gel) for the prevention of
catheter-related infections. For more information about Cadence's pipeline,
Cadence(TM), Acetavance(TM) and Omigard(TM) are trademarks of Cadence
William R. LaRue Anna Gralinska
SVP & Chief Financial Officer Director, Investor Relations
Cadence Pharmaceuticals, Inc. Cadence Pharmaceuticals, Inc.
|SOURCE Cadence Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved